UBQLN2 and amyotrophic lateral sclerosis: The UBQLN2 497H NIL-iMN model can be utilized for high-throughput drug screening to identify compounds that mitigate the toxic effects of UBQLN2 mutations, thereby accelerating the discovery of potential ALS therapies.